Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience by Kane, S.V., Horst, S., Sandborn, W.J., Becker, B., Neis, B., Moscandrew, M., Hanson, K.A., Tremaine, W.J., Bruining, D.H., Faubion, W.A., Pardi, D.S., Harmsen, W.S., Zinsmeister, A.R., Loftus, E.V.

Get full text